Active Ingredient(s): Brolucizumab-dbll
FDA Approved: * October 7, 2019
Category: Vision / Eye Health

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Beovu Overview

Brolucizumab (INN), sold under the trade name Beovu, is a humanized single-chain antibody fragment designed for the treatment of wet age-related macular degeneration (AMD).[1][2] This drug was developed by ESBATech[3][4] (discovery to phase 2a), Alcon Laboratories (phase 2b), and Novartis (phase 3).[citation needed] Laboratory development names are RTH258 (Novartis Compound Code) and ESBA1008 (ESBATech AG). Broluc...

Read more Beovu Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Beovu Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 6mg/0.05ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Beovu: (1 result)

Sorted by National Drug Code
  • 0078-0827 Beovu 6 mg/.05ml Intravitreal Injection, Solution by Novartis Pharmaceuticals Corporation

Other drugs which contain Brolucizumab-dbll or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 8 April 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA